Biofourmis is a global digital health company focused on delivering personalized predictive care. Our clinically validated platform, powered by machine learning and advanced analytics, enables better healthcare, maximizes the effectiveness of high-value drugs, and lowers costs across the entire care continuum.
We partner with pharmaceutical companies to develop clinically-validated prescription digital therapeutics that can be delivered independently or in conjunction with existing pharmacotherapies.
Our pioneering digital therapeutic BiovitalsHF® augments guideline-directed use of heart failure medications to manage patients in combination with traditional pharmacotherapy, and is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).